On 2/26/24, Celldex Therapeutics Inc (NASDAQ: CLDX) stock enjoyed a major increase of 27.8%, closing at $48.23. Moreover, trading volume in this advance was exceptionally high at 640% of normal. The stock has been strong relative to the market over the last nine months and has risen 31.1% during the last week.
Current PriceTarget Research Rating
CLDX’s future returns on capital are forecasted to be in line with the cost of capital. Accordingly, the company is expected to be Value Creation neutral.
Celldex Therapeutics has a current Value Trend Rating of D (Negative). This rating combines very contradictory signals from two proprietary PTR measures of a stock’s attractiveness. Celldex Therapeutics has a very low Appreciation Score of 3 but a slightly positive Power Rating of 69, producing the Negative Value Trend Rating.
Rating Review
In light of this very positive price change we are reviewing our current Overall Rating of D. This review will be completed in the next several days.
Be the first to comment